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Abstract
Background: Limited research exists to guide clinical decisions about trialling, selecting, implementing and
evaluating eye-gaze control technology. This paper reports on the outcomes of a Delphi study that was conducted
to build international stakeholder consensus to inform decision making about trialling and implementing eye-gaze
control technology with people with cerebral palsy.
Methods: A three-round online Delphi survey was conducted. In Round 1, 126 stakeholders responded to
questions identified through an international stakeholder Advisory Panel and systematic reviews. In Round 2, 63
respondents rated the importance of 200 statements generated by in Round 1. In Round 3, 41 respondents rated
the importance of the 105 highest ranked statements retained from Round 2.
Results: Stakeholders achieved consensus on 94 of the original 200 statements. These statements related to person
factors, support networks, the environment, and technical aspects to consider during assessment, trial,
implementation and follow-up. Findings reinforced the importance of an individualised approach and that
information gathered from the user, their support network and professionals are central when measuring outcomes.
Information required to support an application for funding was obtained.
Conclusion: This Delphi study has identified issues which are unique to eye-gaze control technology and will
enhance its implementation with people with cerebral palsy.
Keywords: Accessibility, Eye-gaze control technology, Cerebral palsy, Disabilities, Clinical decision-making, Assistive
technology, Augmentative and alternative communication
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Background
Cerebral palsy is an umbrella term that encompasses a
group of disorders affecting movement and posture. The
primary motor disorder is often accompanied by associ-
ated impairments of sensation, cognition, communica-
tion, perception, behaviour, and/or by seizure disorder
[1]. The type of cerebral palsy and severity of motor in-
volvement play an important role in determining a per-
son’s participation in everyday activities including the
ability to speak. For example, population-based studies
show that one in two children with cerebral palsy have a
speech disorder, and one in three are non-verbal [2].
Speech and motor difficulties may hinder recognition of
a child’s cognitive capabilities, potentially leading to in-
accurate evaluations of strengths and difficulties [3].
Under-estimating a child’s cognitive ability may limit
provision of opportunities for learning and development
as family, peers, educators and health professionals may
not fully realise or respond appropriately to the child’s
developmental profile.
Eye-gaze control technology provides an effective and
direct access method to computers and speech generat-
ing devices for people with significant physical disabil-
ities, such as cerebral palsy [4, 5], who are able to use
purposeful looking behaviours including gaze fixations
and gaze transfers [6–10]. This technology holds the po-
tential to unlock people’s capacity to participate in
leisure and productivity pursuits, play games, listen to
music, use social media, and for environmental control.
For individuals with communication difficulties, it can
also offer access to specialist software for augmentative
and alternative communication (AAC) [8, 10–17]. Eye-
gaze control technology involves an infra-red camera,
which works in conjunction with specialised software, to
monitor and respond to a user’s eye movements [18].
The technology allows a person to move a cursor across
as screen and make on-screen selections by deliberately
fixing their gaze on a target on a screen.
Although literature is available to guide assistive tech-
nology provision [19] and AAC implementation [20, 21],
there is almost none available to support decision-
making concerning the use of eye-gaze control technol-
ogy as an access method. Information is required about
“who” would be the most appropriate candidates, “what”
technology is most effective, “when” it is best intro-
duced, “how” it should be implemented and outcomes
measured [22]. This gap in guidance is highlighted by
two recent systematic reviews which aimed to identify
the effectiveness of eye-gaze control technology as a
method of access, assessment and implementation strat-
egies [22] and appropriate outcome measures [7]. Single
case studies and small group studies, identified in the re-
views, have provided preliminary evidence for use of
eye-gaze control technology with children to achieve
social and communication goals [6, 11, 23, 24], however,
the reviews highlighted a pressing need for research to
inform clinical practice and support funding for this
technology.
Evidence-based practice draws on the best available evi-
dence, clinical expertise and the values and preferences of
recipients of health care [25]. Therefore, this Delphi study
aimed to build international consensus from key stake-
holders to develop evidence- and consumer-informed
clinical guidelines for assessment, trial, implementation,
funding and outcome measurement of eye-gaze control




The Delphi process followed the principles of the Guid-
ance on Conducting and Reporting DElphi Studies
(CREDES) [26]. CREDES was developed to provide guid-
ance to researchers conducting Delphi studies on enhan-
cing the rigour and transparency of reporting and to
support reproducibility and usefulness of research.
CREDES can be used to guide the design of Delphi stud-
ies to enhance methodological rigour (Supplementary
file 1). A 3-round, online Delphi process was used to
identify, and build consensus on, issues that stakeholders
viewed as critical to consider when implementing eye-
gaze control technology for people with cerebral palsy.
Three rounds are conventionally considered sufficient to
enable consensus to be reached [26], minimise respond-
ent fatigue [23] and reduce the risk of attrition with fur-
ther rounds. Three rounds were also feasible within the
resources available to the study [24]. In a Delphi study,
researchers apply a high degree of methodological rigor
to systematically elicit information from respondents
[26–29]. Using an iterative process, researchers seek in-
put from stakeholders across a number of rounds of
structured questionnaires until group consensus is
achieved. The overall study process is presented in Fig. 1
including the dates for each round.
The Delphi process is anonymous and non-
hierarchical so it can elicit open and honest views from
disparate groups such as clinicians, researchers and, in
particular, people with disability and their support net-
work, without group pressure. The process mitigates
against individuals feeling deferential towards clinicians
and researchers, or inhibited by the presence of more se-
nior individuals or stronger voices [27–31]. As an itera-
tive process it allows minority views to be carefully
considered, rather than discarded early in the process
[27]. The process also provides opportunities for partici-
pants to alter their opinions with the benefit of further
consideration, and informed by the collective ideas of
the other participants’ anonymous responses [31].
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Fig. 1 Flowchart of steps involved in completing this project
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An online Delphi process was a particularly suitable
methodology for the current topic as it enabled engage-
ment with large, diverse, international groups of partici-
pants. Additionally, it was intended to facilitate inclusion
of users of eye-gaze control technology and their com-
munication partners (such as parents, partners, families,
caregivers and teachers), as well as clinicians, re-
searchers, industry and funders [26, 28, 30–32].
Consumer and stakeholder involvement
In this study “consumers” are defined as people with
cerebral palsy who are eye-gaze control technology users
and their communication partners, such as family mem-
bers and caregivers. Consumer involvement was embed-
ded in this study from the start; a mother of an
adolescent user of eye-gaze control technology was a
study investigator. In addition, an international Advisory
Panel, comprised of stakeholders from different fields of
interest, informed each stage of the study. See Table 1
for additional details of consumer involvement reported
according to the Short Form of Guidance for Reporting
Involvement of Patients and the Public 2 (GRIPP2-SF)
[33]. These are reporting guidelines developed to en-
hance the quality, transparency and consistency of con-
sumer involvement in research.
Participants and recruitment
Participants were eligible to take part if they were people
with cerebral palsy who used eye-gaze control technol-
ogy, or their family members or caregivers. Other
Table 1 Consumer involvement – Short Form of the Guidance for Reporting Involvement of Patients and the Public
Section and topic Description
1: Aim To incorporate the lived experiences and expertise of consumers into all stages of the study.
2: Methods The investigator team included a consumer investigator, the mother of an adolescent eye-gaze
control technology user.
An Advisory Panel was established to collaborate with the investigators to broaden geographical
representation and expertise. The Advisory Panel comprised a user of eye-gaze control technology,
a parent of a young user of eye-gaze control technology, allied health professionals working as
assistive technology consultants specialising in eye-gaze control technology (two occupational
therapists, three speech pathologists) and one occupational therapist specialising in functional
vision and its assessment. The Advisory Panel and investigator team had members from the
United Kingdom, Belgium, Sweden, the United States of America and Australia. The Advisory Panel
were purposively invited from amongst the research team’s networks to provide diversity of
representation of stakeholder group and geographical location.
Consumers were recruited from amongst the researchers’ networks. Consumers signed a Terms of
Reference which specified the background to the study, purpose and activities of the Stakeholder
Advisory Panel, consumer roles and responsibilities, time frames involved and information about
the operation of the Panel.
Consumers were involved at each stage of the project including input to the ethics application,
reviewing participant information and communications, developing recruitment strategies and
circulating the Delphi to their networks, generating items for the Delphi survey, pilot testing and
analysis of each round of the Delphi survey, reviewing this publication, and collaborating on
knowledge translation.
Communication was managed by video/teleconference and email.
The consumer investigator co-presented findings at an international conference (funded by research
monies) and is a co-author on this paper.




Consumer involvement had substantial impact on all stages of the research.
Comprehension of the recruitment material, participant information and each Delphi survey were
improved and additional critical information included to ensure all were informative and accessible.
Clear advice was given about reducing the length and improving the format of the surveys to
enhance readability and likelihood of participation.
Insightful perspectives about interpreting responses to Round 1 resulted in clarity of themes and
statements to progress to Round 2.




Consumer involvement was central to this study and effectively influenced the quality of each stage.
The consumer investigator was involved very early and collaborated in shaping the study and at each
stage thereafter.
5: Reflections This research may have benefited by increased investigator efforts to more closely support
consumers to be involved, and to increase the numbers of consumers, particularly users of eye-gaze control technology
themselves, to harness greater representation and perspectives, and to have a stronger voice and
impact. This support may include research education and taking time to closely communicate with
individual consumers to ensure that they could engage as thoroughly as possible. It would also be
useful to encourage consumers to communicate amongst themselves to support each other in their
roles.
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eligible participants were professionals who supported
the use of eye-gaze control technology or had been inte-
gral in assessing and/or implementing eye-gaze control
technology for people with cerebral palsy, specifically,
clinicians or technologists, researchers and “others who
identified with these inclusion criteria”.
A link to the electronic Delphi survey was embedded
in an introductory message circulated amongst the local,
national and international electronic networks of the In-
vestigator Team and Advisory Panel, aiming to reach,
via a snowball effect, a range of participants across coun-
tries and settings. The introduction included a video
message from the consumer investigator and her daugh-
ter, inviting participation in the study. Participants who
consented to participate in the study and met the eligi-
bility criteria were directed to the survey. Respondents
who started the survey but indicated they met the
“other” category and not a category for inclusion (i.e., a
person with cerebral palsy, a family member or caregiver
or a professional supporting eye-gaze control technology
for people with cerebral palsy) were thanked for their
interest and exited from the survey and study. In subse-
quent rounds, surveys were sent only to people who had
completed the previous round.
Participant demographics were gathered in Round 1 of
the survey. An email address was obtained from each
participant at each round of the survey to facilitate
reminders and distribution of subsequent rounds of the
survey. The email address was used to link with partici-
pant demographics collected in Round 1 to enable
description of the unique sub-sample responding to sub-
sequent rounds.
Procedures
Generation of content for round 1
As we had identified that there was little evidence to
guide practice, open-ended questions were used in
Round 1 to identify statements which respondents be-
lieved should be included in clinical guidelines. The
questions were developed with the aim of identifying is-
sues related to all aspects of eye-gaze control technology,
spanning identification of the unique contribution and
challenges eye-gaze control technology offers as an ac-
cess method, assessing readiness for eye-gaze control
technology, assessment and outcome measurement, ef-
fective strategies for implementing eye-gaze control
technology, communication partner instruction, costs
and funding [16]. Over a series of meetings, the
Investigator Team and Advisory Panel identified 17
open-ended questions, organised in seven topic areas
(Supplementary file 2) [26]. The questions were written
in English and translated and back-translated to enable
distribution in English, Swedish, Dutch and French –
the languages spoken by the Investigator Team and Ad-
visory Panel.
Survey platform and pilot testing
Research Electronic Data Capture (REDCap - hosted at
University of Sydney) was used as the online platform to
collect responses. This system provides a secure, web-
based application designed to support data capture for
research studies.
Pilot testing of each round of a Delphi survey is con-
sidered best practice [26, 28, 29]. The draft survey of
each round (including study information, items collect-
ing participant characteristics, questions/statements) was
therefore developed, tested in its online form and modi-
fied iteratively by the Investigator Team and Advisory
Panel until agreement was reached that the survey was
rigorous, unambiguous and able to elicit meaningful re-
sponses. Usability on a variety of web browsers on Mac
and Windows-based computers, as well as Android and
iOS-based mobile devices [32] was also checked prior to
dissemination of the survey link. The survey was pre-
pared in accordance with accessibility standards for
people with visual impairment and limited access.
Responses to round 1 of the Delphi survey
The narrative responses to Round 1 were thematically
analysed and the resultant statements, categorised by
theme, were disseminated in Round 2.
Rating of the importance of the statements in rounds 2 and
3 of the Delphi survey
Respondents were asked to rate all statements resulting
from Round 1 in response to the question: How import-
ant is this item to include in clinical guidelines? State-
ments were rated on a 9-point scale where 1–3
corresponded to low importance, 4–6 represented state-
ments that were considered important but not critical,
and statements rated 7–9 were considered to be of crit-
ical importance. An alternative response option (labelled:
don’t know or prefer not to answer) was also provided.
Participants were offered free-text options to expand or
comment on any aspect of their responses. A persona-
lised reminder email was sent to non-responders 1 week
prior to closing Round 2 to optimise survey return rate.
In this round, surveys were offered in English and
Swedish, based on the language of the majority of re-
spondents from Round 1.
Any additional statements identified in the free text
boxes during Round 2, and which did not duplicate
existing content, were analysed thematically and added
as new statements under the appropriate theme.
Statements rated 7–9 by ≥70% of respondents and 1–3
by < 15% of respondents were considered as reaching
consensus, other statements were discarded [34]. The
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process of identifying consensus statements was com-
pleted separately for two groups of participants, all par-
ticipants together and people with cerebral palsy and
their families and caregivers. All statements reaching
consensus from both these groups progressed to Round
3. This process ensured that the most important content
from people with cerebral palsy and their families and
caregivers was included for ongoing consideration. In
the third round, surveys were offered in English and
Swedish.
Data analysis
The thematic qualitative analysis of narrative responses
to Round 1 was performed independently by three inves-
tigators (PK, TG, MW) [35]. The investigators triangu-
lated their responses to reach consensus on themes,
theme titles and statements contained within each theme
to enhance trustworthiness of analyses [31]. To further
minimise bias, the thematic analysis was reviewed by the
Investigator Team and Advisory Panel and revised in an
iterative manner until panel members confirmed
consensus [27]. This process was in lieu of member
checking with the respondents which we avoided in
order to minimise burden, given the already substantial
request to complete 3-rounds of Delphi surveys. The re-
sultant statements, categorised by theme, were dissemi-
nated in Round 2.
SPSS V.25 [36] was used to generate descriptive statis-
tics of participant characteristics and calculate level of
consensus for each statement rated by participants in
Rounds 2 and 3.
Results
Round 1
One hundred and twenty-six participants completed
Round 1 of the Delphi survey (Tables 2 and 3). Twenty
additional people were exited from the survey after indi-
cating that they did not meet the inclusion criteria for
an eligible participant. The total number of potential
participants who received invitations to participate is un-
known due to the snowball nature of recruitment and,
therefore, a response rate could not be calculated for
Round 1.
From the 17 questions 1995 codable units were de-
rived. These were discrete responses to survey questions
which were then collated into 200 thematically uniform
statements. These 200 statements were clustered under
eight themes; including: (1) Unique features of eye-gaze
control technology as an access method; (2) Initial
assessment prior to a trial; (3) Decision making when
conducting a trial of eye-gaze control technology; (4)
Learning, practise and support requirements when
implementing this technology; (5) Evaluation of out-
comes and measures to use; (6) Frequency of follow-up
and review; (7) Informing funding applications and
bodies, and (8) Preparation for possible future access to
eye-gaze control technology if it is not currently appro-
priate. Several issues were common to these eight
themes. Table 4 contains these themes, the correspond-
ing statements and the ratings given to each statement
in subsequent rounds.
Round 2
Sixty-two people responded to 200 statements in Round
2, 49.2% response rate (Tables 2 and 3). One hundred
and five statements progressed to Round 3 for further
consensus building as they were rated 7–9 by ≥70% of
respondents and 1–3 by < 15% of respondents. These
comprised 86 statements identified when responses of
all participants were considered together and a further
19 prioritised by consumers.
Round 3
Forty-one participants responded to Round 3 of the sur-
vey, representing a response rate of 33% in relation to
126 respondents in Round 1 (Tables 2 and 3).
All participants together reached consensus on 93
statements and consumers identified one additional
priority, to reach a total of 94 statements. Of the 19
statements identified as priorities by consumers in
Round 2, nine were rated as priorities by all respondents
in Round 3 and were amongst the final 94 statements in-
cluded in the clinical guidelines. Results for all state-
ments across all three rounds are presented in Table 4.
Discussion
The Delphi study reported here was completed to ad-
dress the gap in evidence to guide implementation of
eye-gaze control technology with people with cerebral
palsy and to inform the content of clinical guidelines for
eye-gaze control technology implementation [6–11, 22].
Consensus was reached on 94 statements considered im-
portant to be included in these clinical guidelines. These
statements were categorised in the eight main themes
outlined in Table 4 and explored in detail below.
Importantly, the consensus achieved through this
international, multiple stakeholder, Delphi process
strongly reinforced that important outcomes for eye-
gaze control technology users included engagement in
play, leisure, recreation and education; enhanced quality
of life and social interaction; control over the environ-
ment; and promoting communication. This is important
evidence to contribute to the justification of funding for
use of eye-gaze control technology as a means of acces-
sing a broad range of technology, and potentially making
a significant impact to the user and their support
network.
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Table 2 Gender, language used by participants, residential area, profession and highest level of education
Round 1
N = 126% (n)
Round 2
N = 62% (n)
Round 3
n = 41% (n)
Gender (female) 86.5 (109) 86.9 (54) 87.8 (36)
Language
English 86.5 (109) 87.1 (54) 87.8 (36)
Swedish 11.1 (14) 1.6 (1) 12.2 (5)
French 1.6 (2) Not offered in French Not offered in French
Dutch 0.8 (1) Not offered in Dutch Not offered in Dutch
Residential area
City 52 (65) 61.3 (38) 70.7 (29)
Regional 28.8 (36) 22.6 (14) 14.6 (6)
Metropolitan 17.6 (22) 14.5 (9) 12.2 (5)
Remote 1.6 (2) 1.6 (1) 2.4 (1)
Countries Great Britain (38%), Australia (15%),
Sweden (15%), USA (14%), Belgium (5%),
Canada (3%) and one participant each
from Afghanistan, Croatia, India, Latvia,
Malaysia, Norway, Slovenia, Spain, Turkey,
Virgin Islands and Zimbabwe.
Great Britain (31%), Sweden (18%),
Australia (16%), USA (13%), Belgium (5%),
Canada (5%) and 1 participant each from
Afghanistan, Croatia, India, Malaysia,
Norway, Slovenia, and Ireland.
Great Britain (29%), Sweden (20%),
Australia (15%), USA (10%), Belgium (5%),
Canada (3%) and one participant each
from Afghanistan, Croatia, India, Malaysia,








24.7 (22) 20.4 (10) 20 (6)
Speech
pathologist
59.6 (53) 55.1 (27) 53 (16)
Biomedical
engineer
2.2 (2) 2.0 (1) 3.3 (1)
Medical
practitioner
4.5 (4) b 4.1 (2) 6.7 (2)
















n = 2 n = 2 n = 2









n = 2 n = 2 n = 2
Speech
pathologist
n = 1 n = 0 n = 0
Unspecified n = 1 n = 0 n = 0
Highest level of education
Tertiary 80.2 (101) 79.0 (49) 78.0 (32)
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Themes identified in the Delphi survey to include in
clinical guidelines
Several issues were common to many of the eight
themes distilled from the Delphi survey. These have
been extracted and presented here to reduce repetition.
Optimal seating and positioning were repeatedly identi-
fied as important for supporting assessment and trial of
eye-gaze control technology and to enable its ongoing
use. Skilled occupational therapists and seating special-
ists are therefore critical members of any team support-
ing use of eye-gaze control technology.
The importance of clinicians possessing up-to-date
knowledge of available technology and current research
and development in the field was identified as important
to enable matching of technology features to users’
needs. In addition, a thorough understanding of how the
technology works, can be adapted to meet a person’s
needs, and support their development and progress, was
considered integral to successful assessment, trials and
ultimately implementation and mastery. Aspects of
knowledge identified as critical include how to select set
up a device which incorprating calibration, configur-
ation, good connectivity, mounting, tailoring (e.g., com-
pensation for some visual difficulties) and how to
upgrade device features.
A multidisciplinary team, with complementary skills
and knowledge, working in partnership with users, fam-
ilies and other members of a person’s support network,
was commonly identified as a priority across the themes
identified in the Delphi survey and is highly consistent
with recommendations in the literature [11, 40–43]. In-
volvement of skilled health professionals in an ongoing
manner to provide education and support to the eye-
gaze control technology user, and others involved in
supporting them, was considered integral to a respon-
sible assessment, trial of the technology and successful
implementation in the different settings in which the
technology should be used.
Unique features of eye-gaze control technology as an
access method
Eye-gaze control technology can be expensive to pur-
chase and complex and time consuming to implement.
Its implementation needs to be tailored to each individ-
ual to best teach, support and enable a user to
participate and communicate across settings and com-
munication partners. Respondents identified features
which are unique to eye-gaze control technology as a
way to justify its use as an access method. These in-
cluded its applicability for people with severe disability
who may have no other available method of directly
accessing technology, or where eye-gaze control technol-
ogy increases efficiency and effectiveness of direct access
to technology when compared to other indirect access
methods, such as switch technology, which requires the
user to scan a menu before selecting the intended target.
Additional features to be considered about eye-gaze con-
trol technology are difficulty using it in outdoor lighting
and the need for careful setup and placement of the
device.
Table 2 Gender, language used by participants, residential area, profession and highest level of education (Continued)
Round 1
N = 126% (n)
Round 2
N = 62% (n)
Round 3
n = 41% (n)
Certificate
qualifications
17.5 (22) 17.7 (11) 19.5 (8)
Secondary 2.4 (3) 3.2 (2) 2.4 (1)
Age groups the participants supported with eye-gaze control technology e
< 6 years 23 (87) 21 (47) 23 (31)
7–14 years 26 (101) 23 (53) 26 (36)
15–24 years 24 (92) 22 (50) 24 (33)
25–44 years 11 (42) 13 (30) 11 (15)
45–64 years 9 (34) 11 (26) 9 (12)
> 65 years 7 (29) 10 (22) 7 (10)
an = 1 did not respond
b Fields of practice for medical practitioners were: Round 1 - paediatrician (neurodisability, neurodevelopment; n = 3), child neurologist (n = 2) and physical
medicine and rehabilitation (n = 1); Round 2 - paediatrician (neurodisability; n = 2), child neurologist (n = 1); and Round 3 - paediatrician (neurodisability; n = 2),
child neurologist (n = 1). Note: some participants nominated two fields of specialty
c The “other” clinicians – were: Round 1 - assistive technology specialist (n = 5), electronic engineer (n = 1), orthoptist (n = 1), psychologist (n = 1) and therapy
assistant (n = 1) [Note: One participant specified more than area]; Round 2 - assistive technology specialist (n = 2), electronic engineer (n = 1), orthoptist (n = 1),
psychologist (n = 1) and AAC specialist (n = 1); and Round 3 - assistive technology specialist (n = 2), electronic engineer (n = 1), psychologist (n = 1) and AAC
specialist (n = 2)
d The work environments of educators were: Round 1 - special schools (n = 3), itinerant roles supporting students in various schools (n = 2) and mainstream school
(n = 1); Round 2 – mainstream school (n = 1), special school (n = 2) and Round 3 - special schools (n = 2)
e Some participants nominated two or more age groups
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Table 3 Characteristics of participants
Round 1
N = 126% (n)
Round 2
N = 62% (n)
Round 3
n = 41% (n)
Respondents
Family/caregivers 9.6 (12) 8.1 (5) 9.8 (4)
Person with cerebral palsy 2.4 (3) 1.6 (1) 0
Classification of functioning a
GMFCS E&R
Level V n = 3 n = 1 n/a c
MACS
Level V n = 2 n = 0 n/a
Level IV n = 1 n = 1 n/a
CFCS
Level IV n = 2 n = 1
Level II n = 1 n = 0 n/a
VSS
Level III n = 2 n = 1 n/a














Family/caregivers 48.1 47.4 46.5
36–62 37–54 36–54
7.7 6.3 7.6
Person with cerebral palsy 58.0 20 b n/a c
54–61
3.6
Clinicians/technologists 41.4 42.2 43.2
22–67 22–67 22–66
11.4 11.6 11.9
Educators 40.8 38 37
22–63 22–55 25–49
16.1 15.8 17.0
Researchers 43.7 43.7 43.7
29–52 29–52 29–52
12.7 12.7 12.7
Other involved with eye-gaze control technology 48.9 66 66
22–75 57–75 57–75
16.8 12.7 12.7
Experience of using/ communication with eye-gaze
control technology (Years)
Family/caregivers 3.5 3.5 2.75
< 1 to 6 1 to 6 < 1 to 6
2.1 2.2 2.8
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Initial assessment
One in three people with cerebral palsy has a vision dif-
ficulty [44], a consideration in using most means of
AAC. Respondents identified that a vision assessment
[45], including evaluation of functional vision abilities
[46], acuity, visual perception and visual motor integra-
tion, was required to assist in implementing eye-gaze
control technology [47]. Functional vision refers to the
use of vision in everyday activities [48]. For those who
are not vision specialists, aspects of functional vision can
be described using the Visual Function Classification
System [49] and the Eye-Pointing Classification Scale
[50]. Notably, respondents clearly indicated that vision
difficulties should not necessarily preclude opportunities
to trial eye-gaze control technology since the technology
has the capacity to be calibrated to accommodate some
difficulties with vision.
Cerebral palsy frequently co-occurs with cognitive dif-
ficulties with 30–40% of children with cerebral palsy
have an intellectual disability. The assessment of cogni-
tion can be challenging in people with sever motor im-
pairment who have little or no functional speech, and to
date we lack appropriate standardised tools for assessing
cognition in this population [3]. Respondents did not
identify that understanding of cognitive ability or ability
to demonstrate cause and effect were priorities as part of
an initial assessment. Respondents reported that people
should not be precluded from the opportunity to trial
eye-gaze control technology as, for some individuals,
eye-gaze control technology may provide the means to
explore cause and effect activities for the first time.
However, if the purpose of introducing eye-gaze control
technology as an access method is to facilitate communi-
cation, establishing a profile of cognitive and language
ability is important in guiding implementation of the
technology and will be a factor to consider when setting
goals and managing consumer expectations. Successful
AAC users and their support networks attribute success
to the cognitive strengths of the user [51]. Equally, chil-
dren without knowledge that their actions can cause an
effect on objects, for example in the context of play, may
struggle to engage meaningfully with eye-gaze control
technology.
The trial
Several factors were considered by respondents to be im-
portant when making the decision to carry out a trial of
eye-gaze control technology, including the person’s pref-
erences, goals of using the device and the readiness of
the team around the person. The literature suggests that
people making informed choices about using assistive
technology will need opportunities to trial different types
of equipment to establish their preferences and to dis-
cuss the implications of their options [43]. The risk of
device abandonment is likely to reduce when people
who use assistive technologies are involved in decision
making [19].
Respondents considered that trials need to be con-
ducted in collaboration with clinicians and other stake-
holders and duration of follow up needs to be long
enough for the user to have the opportunity to practice
and demonstrate skill development and achievement of
goals. As a result, no consensus was reached on the
exact length of time that is required for a trial as it will
vary from individual to individual. Tailoring the length
of device trials to an individual’s needs and progress is
consistent with a person-centred approach to service de-
livery [52].
Respondents identified that goals which were collab-
oratively developed between the person with cerebral
palsy, their support network and clinicians, and which
drove a clear plan and identification of roles and respon-
sibilities were a high priority for a successful device trial.
Motivating activities for trialing and practising the tech-
nology, which were aligned with the person’s goals and
interests, were reported to be crucial considerations and
underscored a need for clinicians to understand the pri-
orities and interests of the person.
Learning, practise and support
There was strong consensus that practise, through activ-
ities or games, was required to ensure effective imple-
mentation of eye-gaze control technology. Respondents
recommended that practise should take place in regular
but short sessions to optimise learning and minimise the
potential impact of fatigue on performance. Of particular
clinical relevance, is the recommendation that practise
Table 3 Characteristics of participants (Continued)
Round 1
N = 126% (n)
Round 2
N = 62% (n)
Round 3
n = 41% (n)
Person with cerebral palsy 2.3 9 b n/a c
0–5 years
2.5
a GMFCS E&R Gross Motor Function Classification System Expanded and Revised [37]; MACS Manual Ability Classification System [38]; CFCS Communication
Function Classification System [39]; VSS Viking Speech Scale [40]
b Only one person with cerebral palsy in this round
c No people with cerebral palsy in this round
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should be embedded in the routines of the person learn-
ing to use the technology, rather than taking place in
specifically arranged practice sessions.
Ongoing education, practise and support, with an indi-
vidualised plan, were recommended for the user and
their support team to ensure they were competent and
confident to optimise the outcomes of the eye-gaze con-
trol technology. The statements relating to these consid-
erations are aligned with what has been reported in the
general assistive technology and AAC literature [53–59].
Input from skilled professionals was considered a prior-
ity for guiding and coordinating device implementation
and in tailoring and upgrading the technology for an in-
dividual. Timely, technical support and ongoing review
of technology implementation, as required or requested
by a user and their support network, were identified as
integral to the success of eye-gaze control technology.
These statements reflect those raised during a Global
Research innovation and Education summit on Assistive
Technology (GREAT) held in 2017 [60].
Outcome measures
Delphi respondents clearly indicated that the key meas-
ure of the outcome of eye-gaze control technology was
the individual user’s goal achievement supplemented by
observations from other relevant professionals. These
goals need to be related to the purposes for which they
were using the technology and co-constructed between
the person using the technology and their support
network. No evidence-based outcome measures were
identified as a priority for use. The Investigators and Ad-
visory Panel are concerned that funding agencies may
require standardised measures with evidence of reliabil-
ity and validity to supplement the individualised
measures. Examples of such measures include Goal At-
tainment Scaling (GAS) [61], Family Impact of Assistive
Technology Scale for Augmentative and Alternative
Communication (FIAT-AAC) [62] and Therapy Out-
come Measure (TOM-AAC) [63].
Some respondents reported that outcome measures
were not accessible in their language or they were un-
familiar with the measures, indicating a need for further
education and efforts to translate existing measures into
languages other than English, and to develop new tools
that reflect cultural and linguistic diversity.
Funding considerations
The way in which eye-gaze control technology is funded
varies from country to country, and potentially within
countries. A newly published position paper on an inter-
national framework for assuring availability and accessi-
bility of assistive technologies supports this assertion
[19]. Respondents identified that sufficient evidence
needs to be provided to meet local funding criteria along
with proof that a support network of health profes-
sionals and people within the user’s various environ-
ments was available and committed to supporting
implementation. While attending to local funders’ cri-
teria, respondents also strongly identified that evidence
of effects across a broad range of outcomes should be of-
fered, including participation in leisure and productivity
occupations, environmental control and enhanced com-
munication, social interaction and quality of life.
Preparation for possible future access
The Delphi survey sought information on actions which
could be taken to develop the skills of a person and their
families and caregivers, when initial trials had not been
successful, but the team around the person still
recognized that re-introduction of eye-gaze control tech-
nology at a later date may present new opportunities.
Respondents recommended ensuring well supported
seating and positioning and developing competencies to
optimise the likelihood of success of a future trial. These
competences included supporting the development of
functional vision skills as well as enhancing communica-
tive competence and confidence of both users and their
communication partners through encouraging use of
looking behaviors for communication such, as eye-
pointing, in low-tech methods of communication and
choice making. Different AAC systems and strategies re-
quire varying degrees of cognitive skill for successful
use. Research with people with traumatic brain injury
suggests that using a multimodal approach where the
person is supported using low-tech solutions, such as
eye-pointing to make choices, in addition to high-tech
solutions [64] can help build communicative compe-
tence and confidence.
Limitations
While the field of assistive technology is multidisciplin-
ary, the majority of respondents were either occupational
therapists or speech and language therapists. The find-
ings, therefore, largely reflect the particular perspectives
of these health professionals who, nevertheless, are
recognised as primary agents for the support of eye-gaze
control technology. Fewer people with cerebral palsy
completed Rounds 1 and 2 compared to other stake-
holder groups, and none completed Round 3, despite the
investigators’ active engagement with consumers as part
of the investigator team and Advisory Panel to co-design
and optimise dissemination of the surveys. The surveys
were long, time-consuming and would, undoubtedly,
have been taxing to complete. The impact of the limited
representation of people with cerebral palsy and their
communication partners on the findings of this study is
unknown. Future studies will need to diligently attend to
creative and accessible means for ensuring consumers’
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voices contribute to findings. Although, consumers’ re-
sponses to this Delphi study were analysed separately to
preference their views, communicating the findings of
this study will need to be cognisant of the near-absence
of consumer contributions and perspectives. Particular
attention will also need to be paid to evaluating the im-
pact of the findings for people with cerebral palsy and
their support networks to ensure that knowledge transla-
tion strategies can be responsive to their needs for infor-
mation and guidance about use of eye-gaze control
technology.
The Delphi surveys requested information relevant
to children, adolescents and adults with cerebral
palsy. Although age-group-specific information was
not obtained, the respondents supported eye-gaze
control technology users across all age ranges and the
findings offer guidance for use across the lifespan.
Evaluation of our implementation of the findings will
seek to identify additional considerations for different
age groups and abilities.
Attrition is a feature of Delphi studies due to the
multiple rounds [28]. The response rate declined with
each round of this study, as expected, although the
overall response rate of 33% in Round 3 is about 10
percentage points more than anticipated [65]. We
sent personalised links to participants and reminder
emails as a strategy to enhance the response rate.
The complexity and importance of the topic meant
that there were a large number of statements to rate
in Rounds 2 and 3, which may have been burdensome
and contributed to attrition. The proportion of partic-
ipants from each stakeholder group did not change
appreciably across rounds, with the exception of not-
ably fewer educators and a reduction in numbers of
people with cerebral palsy from three in Round 1 to
none in Round 3. The relative contribution of the
various stakeholder groups to the ratings of state-
ments is therefore likely to be similar across rounds.
The impact of attrition and the few contributions
from consumers on the final selection of statements
is not possible to ascertain.
Conclusions
Participants in this Delphi process achieved consen-
sus for 94 statements across eight domains for eye-
gaze control technology implementation: its unique
role in meeting the needs of a user; initial assess-
ment; trial; learning, practise and support; follow up;
outcome measures; funding considerations and prep-
aration for eye-gaze control technology as a possible
future access method. These statements will form the
core of evidence- and consensus-informed clinical
guidelines - the scope, content and implementation
of which will further our knowledge in the field.
These guidelines will be crafted in collaboration with
an expanded Advisory Panel selected to ensure
greater representation of consumers. The guidelines
have the potential to evolve as our knowledge ad-
vances and evaluation of guidelines implementation
informs subsequent iterations. The guidelines will be
made freely available and accessible online and will
contain specific guidance about implementation and
evaluation of eye-gaze control technology for people
with cerebral palsy including links to relevant evi-
dence and resources.
Findings from the Delphi process strongly recom-
mended that the clinical guidelines complement and
support clinicians and consumers in their quest for
finding, assessing and implementing eye-gaze control
technology as an access method. The importance of
realistic goals and a plan for implementation of eye-
gaze control technology, along with provision of edu-
cation and support for the user and their support
network, including their communication partners were
emphasised.
The findings may have relevance for other poten-
tial users of eye-gaze control technology such as
people with Amyotrophic Lateral Sclerosis and
Locked-in Syndrome. There are important differ-
ences between people with cerebral palsy who have
sustained damage to the developing brain and these
other, adult onsets, conditions in terms of the mech-
anism of physical disability, existence of co-
morbidities (hearing, vision, epilepsy, cognition) and
environmental exposures across the lifespan.
The findings from this Delphi study and the result-
ant clinical guidelines have the potential to further
advance our knowledge of how to best support people
with disabilities gain access to technology to enable
participation in communication, work, education and
leisure pursuits. Future research will focus on the
free, online clinical guidelines and complementary re-
sources developed from the findings of this Delphi
study. Effective knowledge translation strategies, co-
developed with people with cerebral palsy, their fam-
ilies, clinicians, funders and researchers, will be re-
quired to support and evaluate uptake of the clinical
guidelines to ensure they reach and are implemented
by intended stakeholders. The impact of implement-
ing the clinical guidelines on outcomes considered
meaningful by people with cerebral palsy and their
communication partners is also required. Further-
more, future research to identify the relationships be-
tween functional vision and eye-gaze control, and
between motor types of cerebral palsy, severity and
eye-gaze control will assist clinicians to further tailor
eye-gaze control technology implementation to opti-
mise success.
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